Table 5 lists adverse reactions as follows: Oculogyric crisis Visual disturbance. Posology Adults A low initial dose is recommended, which subsequently may be adjusted according to the patient’s response. Examples of medicinal products that may increase haloperidol plasma concentrations based on clinical experience or drug interaction mechanism include:. The relevance of these tumour findings in rodents in terms of human risk is unknown. The syndrome is mainly characterized by rhythmic involuntary movements of the tongue, face, mouth or jaw. Dystonic symptoms can include, but are not limited to, torticollis, facial grimacing, trismus, tongue protrusion, and abnormal eye movements, including oculogyric crisis.

Uploader: Tojabei
Date Added: 17 September 2005
File Size: 23.83 Mb
Operating Systems: Windows NT/2000/XP/2003/2003/7/8/10 MacOS 10/X
Downloads: 96051
Price: Free* [*Free Regsitration Required]

Treatment of tic disorders, including Tourette’s vose, in patients with severe impairment after educational, psychological and other pharmacological treatments have failed.

If patients miss a dose, it is recommended that they take the next dose as usual, and do not take a double dose. Respiratory depression may necessitate artificial respiration.

Haldol 2mg/ml oral solution – Summary of Product Characteristics (SmPC) – (eMC)

Small amounts of haloperidol have been detected in plasma and urine of breast-fed newborns of mothers treated with haloperidol. OR Child resistant, polypropylene screw-cap with low density polyethylene insert.

By continuing to browse the site you are agreeing to our policy on the use of cookies. The influence of renal impairment on the halooperidol of haloperidol has not been evaluated.

The frequency is unknown.


Plasma concentrations measured at various time points and after various durations of treatment, were either undetectable or ranged up to a maximum of Peak plasma levels of haloperidol are generally attained within 2 to 6 hours of oral dosing. Over the course of a typical 10 week controlled study, the rate of death in patients treated with antipsychotics was about 4. Haloperidol causes efficient psychomotor sedation, which explains the favourable syringf on mania and other agitation syndromes.

Haloperidol suppresses delusions and hallucinations as a direct consequence of blocking dopaminergic signalling in the mesolimbic pathway. The possible increase in intraocular pressure must be considered when anticholinergic medicinal products, including antiparkinson medicinal products, are administered concomitantly with HALDOL.

Haldol 2mg/ml oral solution

Dose adjustment is recommended in elderly patients see section 4. Respiratory, thoracic and mediastinal disorders. Hyperprolactinaemia may suppress hypothalamic GnRH, resulting in reduced pituitary gonadotropin secretion. Dkse increased Weight decreased. If concomitant treatment with an antiparkinson medicinal product is required, it may have to be continued after stopping HALDOL if its excretion is faster than that of haloperidol in order to avoid the development or aggravation of extrapyramidal symptoms.

Switch from mania to depression There is a risk in the treatment of manic episodes of bipolar disorder ddose patients to switch from mania to depression.

This increase may be higher with all butyrophenones, including haloperidol. Examples of medicinal products that may increase haloperidol plasma concentrations based on clinical experience or drug interaction mechanism include: Do not refrigerate or freeze.


Gradual withdrawal is advisable as a precautionary measure. Haloperidol apparent clearance dosee extravascular administration ranges from 0.

The risk of ventricular arrhythmias, possibly associated with QTc prolongation, must be considered. In cases of severe extrapyramidal reactions, doe administration of an antiparkinson medicinal product is recommended. However, there have been isolated case reports of birth defects following foetal exposure to haloperidol, mostly in combination with other medicinal products.

Mechanism of action Haloperidol is an antipsychotic belonging to the butyrophenones group.

Treatment of persistent aggression and psychotic symptoms in patients with moderate to severe Alzheimer’s dementia and vascular dementia when non-pharmacological treatments have failed and when there is a risk of harm to self or others.

There is a high inter-subject variability for plasma protein binding. These studies included mainly children and adolescents aged between 2 and 17 years. Tardive dyskinesia may appear in some patients on long-term therapy or after discontinuation of the medicinal product. The use of haloperidol has been associated with the development of akathisia, characterised by a subjectively unpleasant or distressing restlessness and need to move, often accompanied by an inability to sit or stand still.

Continue typing to refine. To bookmark a medicine you must sign up and log in.

Author: admin